We develop therapeutic vaccines to meet the growing need for improved anti-cancer treatments
Our unique and innovative scientific research, and our improved understanding of immunological mechanisms, is at the heart of Vaxeal’s mission to deliver cutting-edge therapies. Our vaccines address a wide spectrum of tumors aiming to improve long-term survival with limited adverse effects.
Patient quality of life
Vaxeal strives to promote quality of life for cancer patients by developing breakthrough therapeutic vaccines. The strategy resides in the restoration of appropriate immune responses in these patients using an innovative combined vaccine strategy thus overcoming the limitations to current vaccine approaches.
Vaxeal is conducting extensive pre-clinical studies with human cells, from healthy donors and cancer patients, and in transplantable and spontaneous animal tumor models to predict the immunogenicity and therapeutic efficacy of the tumor vaccines developed in humans.
Vaxeal’s clinical portfolio is the result of 15 years of research and is unique in the biopharmaceutical sector. It is protected by numerous patents and is at the heart of Vaxeal’s anti-cancer therapeutic vaccines platforms. Each product developed at Vaxeal addresses major unmet medical needs.
Vaxeal has established long-term strategic partnerships with leading oncology research and clinical centers in order to optimize its R&D capabilities in order to access to the most advanced technologies, as well as state of the art knowledge.